Clarity Pharmaceuticals (ASX:CU6): Prostate Cancer Trials and Clinical Development Update

Aditi Sarkar

22 October 2026 04:20 PM AEDT

Clarity Pharmaceuticals (ASX:CU6): Prostate Cancer Trials and Clinical Development Update

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Clarity Pharmaceuticals (ASX:CU6) reached the recruitment target for the SECuRE cohort expansion main group in October 2026.
The main group enrolled 16 participants receiving up to six cycles of copper-67 SAR-bisPSMA.
An August analysis reported PSA declines of at least 50% in 63% of evaluable participants at the 8 GBq dose level.
The December 2025 half-year report recorded an AUD 55.7 million loss and AUD 226.2 million in liquid assets.

Clarity Pharmaceuticals Limited (ASX:CU6) develops copper-based radiopharmaceuticals for cancer imaging and treatment, using its proprietary SAR Technology platform. The company’s recent clinical disclosures concern prostate cancer diagnostic studies and the SECuRE therapeutic trial. On 22 October 2026, Clarity Pharmaceuticals (ASX:CU6) was priced at AUD 1.67, down 6.18% for the trading session. In October, Clarity confirmed that the principal cohort expansion group of SECuRE had met its recruitment target, while enrolment in a combination-treatment arm continued.

Company Business

Clarity Pharmaceuticals (ASX:CU6) is a clinical-stage developer rather than a commercial manufacturer of approved cancer medicines. Its technology pairs copper-64 for positron emission tomography imaging with copper-67 for targeted radiation treatment. The SAR-bisPSMA program focuses on prostate cancer, including diagnostic imaging and treatment of metastatic castration-resistant disease. Other development programs include SARTATE for neuroendocrine tumour imaging and SAR-Bombesin for prostate cancer imaging. Clinical activities extend to the United States and Australia.

The diagnostic portfolio includes the CLARIFY and AMPLIFY Phase III studies of copper-64 SAR-bisPSMA. Both evaluate imaging in different prostate cancer settings. Separate clinical work tests copper-67 SAR-bisPSMA as a therapeutic agent. These investigational products remain subject to trial results, regulatory review and the requirements of radioactive medicine manufacturing and distribution.

Recent Development

On 8 October 2026, Clarity Pharmaceuticals (ASX:CU6) announced that recruitment into the SECuRE cohort expansion main group had reached 16 participants. That group assesses up to six cycles of 8 GBq copper-67 SAR-bisPSMA in patients with metastatic castration-resistant prostate cancer. Recruitment continued for a separate group receiving the investigational treatment alongside enzalutamide, an androgen receptor pathway inhibitor. The wider expansion design assesses treatment with and without the combination regimen.

The company’s August update examined 19 participants at the 8 GBq dose level, with a median of two treatment cycles at the assessment point. Among evaluable participants, 74% recorded a prostate-specific antigen reduction of at least 25%, while 63% reached at least 50%. Among 16 participants evaluable by imaging, 81% had disease control. These early-stage findings do not establish clinical efficacy in a registrational trial or regulatory approval.

Clarity also reported seven instances of complete response or undetectable disease across its copper-67 SAR-bisPSMA clinical development program, based on the applicable assessment methods. The company intends to release additional cohort expansion data as follow-up matures and has discussed planning for a subsequent Phase III therapeutic study.

Financial Performance and Sector Context

For the six months ended 31 December 2025, Clarity Pharmaceuticals (ASX:CU6) recorded an AUD 55.7 million net loss, compared with AUD 23.5 million in the corresponding comparative half-year. Research and development expenditure increased by AUD 21.9 million to AUD 50.5 million as clinical trial work expanded. These expenditures reflect the company’s development-stage operating model rather than revenue from commercialised therapies.

At 31 December 2025, liquid assets totalled AUD 226.2 million, comprising AUD 70.5 million in cash and AUD 155.8 million in term deposits. Net assets were AUD 232.8 million. In May 2026, the company announced receipt of an approximately AUD 9.8 million Australian research and development tax incentive refund. These figures describe different reporting dates and should not be combined as a current cash balance.

Radiopharmaceutical development depends on controlled isotope production, clinical supply, specialist treatment infrastructure and regulatory oversight. Clarity signed a commercial manufacturing agreement for copper-64 SAR-bisPSMA in April 2026, addressing part of the production arrangements that would be relevant if its diagnostic product progresses through the approval process.

Risks to Consider

Clarity Pharmaceuticals (ASX:CU6) faces clinical-development uncertainty, including the possibility that preliminary observations are not reproduced in larger trials. Enrolment rates, patient follow-up, product safety, manufacturing consistency and regulatory requirements can affect study schedules. Continued research and development spending may also reduce liquid assets before any significant product revenue is established.

What to Watch Next

The next disclosures to monitor include maturing SECuRE data, enrolment of the enzalutamide combination group, and the planned design of a registrational therapeutic trial. Readouts from the CLARIFY and AMPLIFY diagnostic studies are also important. The company has scheduled its annual general meeting for 25 November 2026, while subsequent financial reports will clarify cash use and development expenditure.

Key Insights

Clarity Pharmaceuticals (ASX:CU6) has advanced recruitment in the SECuRE expansion study while progressing separate prostate cancer imaging trials. The latest disclosed half-year results show a development-stage loss alongside substantial liquid assets at the reporting date. Trial maturity, regulatory progress, manufacturing arrangements and cash requirements remain central measurable factors in assessing subsequent company announcements.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.